Radiation Oncology-Biology Integration Network on Oligometastasis (ROBIN OligoMET) Center

转移是一个复杂的系统问题，在细胞、组织、器官和生物体尺度上发生关键变化。 目前治疗转移性患者的疗效有限，这表明我们还没有完全了解转移。 前列腺癌（PCa）的转移能力表现为沿着一系列疾病， 寡转移状态，其中转移的数量和位置有限。所有肿瘤的放射巩固 在寡转移性PCa中沉积以阻止进一步进展的方法现在得到了以下小型随机研究的支持： 循环设置，但在从头空间的效用是未知的。这些都是重要的早期临床数据 这表明存在寡转移状态和辐射巩固在改变中的重要性， 潜在的转移倾向，这对这些患者的管理有直接的影响。U54 罗宾Oligometastasis（罗宾OligoMET）中心汇集了来自美国大学的杰出教师， 马里兰州（UM），威尔康奈尔医学（WCM）和托马斯杰斐逊大学（TJU）研究的机制， 放射治疗（RT）如何影响原发性寡转移性PCa的转移过程。这 多学科的视角使我们能够将最新的临床试验，分析和计算方法， 与寡转移的最临床相关方面有关。这反过来又会导致新的发展。 使用RT来对抗转移的方法。这个U 54 ROBIN OligoMET中心将由Drs. Tran，Nicole Simone和Amit Sawant（MPI）。项目领导层由具有深厚背景的教师组成 放射生物学、物理学和转移研究：领导项目1（基因组学、放射组学和液体活检） 由Tran，Ren和Sawant博士领导;项目2（代谢组学和差异）由Simone博士领导;资源 共享和交叉训练核心由Luigi Marchionni，Sawant和Ren博士领导。我们带来了多样化的 模型系统、实验方法和概念框架。这些项目融合了最先进的 来自人类的组织、液体和放射组学多参数分析技术， 小鼠肿瘤模型在第一次在人2期随机试验的背景下。数据将使用新的 网络方法，以优先考虑跨项目的功能验证候选人。科学和后勤 将通过一个行政核心确保一体化。多组学分析和整合，定量图像 分析和网络分析将在交叉训练核心中进行。ROBIN OligoMET中心将 检验巩固辐射可以改变癌细胞状态可塑性和宿主肿瘤的整体假设 促进转移形成的代谢。目的#1 -识别癌细胞内在和肿瘤微环境 由辐射调节的可塑性机制改变转移倾向。目标#2 -确定代谢 调节非裔美国人与高加索人寡转移性抗肿瘤免疫和转移的变化 SABR巩固后的前列腺癌。目标#3 -与培训计划相结合的多规模集成 致力于阐明巩固性SABR后转移性癌症的新治疗弱点。

Metastasis is a complex systems problem, with critical changes across cell, tissue, organ, and organism scales. The limited efficacy of current therapies in metastatic patients argues that we do not fully understand metastasis. The metastatic capacity of prostate cancer (PCa) behaves along a spectrum of disease that contains an oligometastatic state where metastases are limited in number and location. Radiation consolidation of all tumor deposits in oligometastatic PCa to forestall further progression is now backed by small randomized studies in the recurrent setting, but the utility in the de novo space is unknown. These are important early clinical data suggesting the existence of an oligometastatic state and the importance of radiation consolidation in altering underlying metastatic proclivity which has immediate impact for the management of these patients. Our U54 ROBIN Oligometastasis (ROBIN OligoMET) Center brings together pre-eminent faculty from the University of Maryland (UM), Weill Cornell Medicine (WCM) and Thomas Jefferson University (TJU) to study mechanisms of how radiation therapy (RT) can affect the metastatic process in de novo oligometastatic PCa. This multidisciplinary perspective enables us to bring the latest clinical trial, profiling and computational methods to bear on the most clinically relevant aspects of oligometastasis. This in turn will lead to the development of new approaches for using RT to combat metastases. This U54 ROBIN OligoMET Center will be led by Drs. Phuoc Tran, Nicole Simone and Amit Sawant (MPI). Project leadership comprises faculty with strong backgrounds in radiation biology, physics and metastasis research: Project 1 (Genomics, radiomics and liquid biopsies) is led by Drs. Tran, Ren and Sawant; Project 2 (Metabolomics and disparities) is led by Dr. Simone; and the Resource Sharing and Cross-Training Cores are led by Drs. Luigi Marchionni, Sawant and Ren. We bring a diversity of model systems, experimental methods, and conceptual frameworks. The projects integrate state-of-the-art tissue, liquid and radiomic multi-parametric profiling techniques from humans complimented with syngeneic mouse tumor models in the context of a first-in-man phase 2 randomized trial. Data will be integrated using novel network methods to prioritize candidates for functional validation across projects. Scientific and logistical integration will be ensured by an Administrative Core. Multi-omics analysis and integration, quantitative image analysis, and network analysis will be conducted in the Cross-Training Core. The ROBIN OligoMET Center will test the global hypothesis that consolidative radiation can alter cancer cell state plasticity and host-tumor metabolism that drives metastasis formation. AIM #1 – Identify cancer cell intrinsic and tumor microenvironment plasticity mechanisms modulated by radiation that change metastatic proclivity. AIM #2 – Determine metabolic changes that regulate anti-tumor immunity and metastasis in African American versus Caucasian oligometastatic prostate cancer following SABR consolidation. AIM #3 – Multi-scale integration embedded with training initiatives towards the elucidation of novel therapeutic vulnerabilities of metastatic cancers following consolidative SABR.